---
document_datetime: 2023-09-21 17:22:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/revasc-epar-all-authorised-presentations_en.pdf
document_name: revasc-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.794811
conversion_datetime: 2025-12-19 13:22:29.877313
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EU Number Invented name Strength Pharmaceutical form Route of administration Packaging Fill volume (concentration) Package size

| EU/1/97/043/001   | Revasc   | 15 mg   | Powder and solvent for solution for injection   | Subcutaneous use   | Powder: vial (glass) Solvent: ampoule (glass)   | Powder: 15 mg Solvent: 0.5 ml (15 mg/ 0.5 ml)   | 2 vials + 2 ampoules   |
|-------------------|----------|---------|-------------------------------------------------|--------------------|-------------------------------------------------|-------------------------------------------------|------------------------|
| EU/1/97/043/002   | Revasc   | 15 mg   | Powder and solvent for solution for injection   | Subcutaneous use   | Powder: vial (glass) Solvent: ampoule (glass)   | Powder: 15 mg Solvent: 0.5 ml (15 mg/ 0.5 ml)   | 10 vials + 10 ampoules |
| EU/1/97/043/003   | Revasc   | 15 mg   | Powder and solvent for solution for injection   | Subcutaneous use   | Powder: vial (glass) Solvent: ampoule (glass)   | Powder: 15 mg Solvent: 0.5 ml (15 mg/ 0.5 ml)   | 1 vial + 1 ampoule     |

## Revasc 15 mg Powder and solvent for solution for injection Subcutaneous use Powder: vial (glass) Solvent: ampoule (glass) Revasc 15 mg Powder and solvent for solution for injection Subcutaneous use Powder: vial (glass) Solvent: ampoule (glass) Revasc 15 mg Powder and solvent for solution for injection Subcutaneous use Powder: vial (glass) Solvent: ampoule (glass) Medicinal product no longer authorised